Roger Longman
The American Heart Association meeting in November was as notable for the news that didn’t get announced there as for...
Although cardiovascular drugs represent the biggest category in pharmaceutical sales, dealmaking has been surprisingly slight compared to other therapeutic areas. The low activity level reflects minimal progress in creating novel medicines and the clinical risk and cost innovators face.
Roger Longman
The American Heart Association meeting in November was as notable for the news that didn’t get announced there as for...
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.